Andrea Bloch
Psychiatry · Bethlehem, PANPI 1487790705
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 97.9% of the total across 276 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 24 manufacturers, the largest accounting for just 18.9% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2024 at $2,065 and has fallen 99.1% since, to $18 in 2025. Among psychiatry clinicians in PA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 276 payments — averaging $20.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Otsuka America Pharmaceutical, Inc.$1K
- Johnson & Johnson$660
- AbbVie$655
- Alkermes, Inc.$633
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$517
- Lundbeck LLC$479
- plus $2K from 18 others
What the payments were for
- Food & beverage$5,61498%
- Education$1192%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 36 | $1,085 |
| Johnson & Johnson | 27 | $660 |
| AbbVie(2 entities) | 34 | $655 |
| Alkermes, Inc. | 30 | $633 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 18 | $517 |
| Lundbeck LLC | 42 | $479 |
| Bausch Health US, LLC | 18 | $329 |
| Neurocrine Biosciences, Inc. | 15 | $294 |
| Sunovion Pharmaceuticals Inc. | 18 | $270 |
| Teva Pharmaceuticals USA, Inc. | 12 | $264 |
| Ironshore Pharmaceuticals Inc. | 1 | $92 |
| Axsome Therapeutics, Inc. | 4 | $84 |
| Jazz Pharmaceuticals Inc. | 3 | $54 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $47 |
| Vanda Pharmaceuticals Inc. | 2 | $43 |
| Neos Therapeutics, LP | 3 | $40 |
| AstraZeneca | 1 | $39 |
| Avanir Pharmaceuticals, Inc. | 2 | $35 |
| Vertical Pharmaceuticals, LLC | 2 | $30 |
| Braeburn Inc. | 1 | $22 |
| Shire North American Group Inc | 1 | $19 |
| Tris Pharma Inc | 1 | $16 |
| E.r. Squibb & Sons, L.L.C. | 1 | $15 |
| Currax Pharmaceuticals LLC | 1 | $10 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- REXULTI$250
- CAPLYTA$249
- ABILIFY MAINTENA$238
- VRAYLAR$238
- ABILIFY ASIMTUFII$125
How this compares
$5,733 in reported general payments places this provider in the 90th percentile of 1,838 psychiatry providers in Pennsylvania.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Escitalopram Oxalate | 14 | $180 |
Paid to pharmacies, not to this prescriber.
Other psychiatry in Bethlehem
- Abel GonzalezBethlehem$74K
- Rebecca RomaPittsburgh$3.3M
- Robert NelsonWyomissing$2.2M
- Matthew BergerMoosic$1.7M
- Mark MattaNew Castle$847K
- Mayer AyyashPittsburgh$714K
- Daniel WeintraubPhiladelphia$647K
- Sachin MehtaBlue Bell$646K
- Jane JesseKingston$617K
- Michael ThasePhiladelphia$396K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.